Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:08:30.266Z.
Calculation as of: 2026-10-06T17:08:30.266Z.
Quote observation: 2026-10-06T17:04:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fc0b38e6dc372860fd9bea61ccff40ee6de978c8f50a2bbdf53c6942eb71849
PEG RATIO
N/A
Quince Therapeutics, Inc.
Market Cap
$7.66M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.66M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.40M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.93M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.08M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
